Market closedNon-fractional

Alimera Sciences/ALIM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Alimera Sciences

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Ticker

ALIM

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Alpharetta, United States

Employees

157

Alimera Sciences Metrics

BasicAdvanced
$291M
Market cap
-
P/E ratio
-$0.61
EPS
1.15
Beta
-
Dividend rate
$291M
1.15
2.62
2.335
175.758
177.736
-0.08%
-0.58%
-197.04%
2.3
7.2
-5.44
-2.354
61.75%
-74.94%
23.84%
-25.22%

What the Analysts think about Alimera Sciences

Analyst Ratings

Majority rating from 4 analysts.
Buy

Alimera Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-26.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$23M
-12.55%
Net income
-$6.2M
67.57%
Profit margin
-26.95%
91.68%

Alimera Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 111.76%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.32
-$0.06
-$0.07
-$0.12
-
Expected
$0.02
-$0.06
$0.00
-$0.06
-$0.04
Surprise
-8,900.00%
-6.98%
-∞%
111.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alimera Sciences stock?

Alimera Sciences (ALIM) has a market cap of $291M as of July 06, 2024.

What is the P/E ratio for Alimera Sciences stock?

The price to earnings (P/E) ratio for Alimera Sciences (ALIM) stock is 0 as of July 06, 2024.

Does Alimera Sciences stock pay dividends?

No, Alimera Sciences (ALIM) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Alimera Sciences dividend payment date?

Alimera Sciences (ALIM) stock does not pay dividends to its shareholders.

What is the beta indicator for Alimera Sciences?

Alimera Sciences (ALIM) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Alimera Sciences stock

Buy or sell Alimera Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing